External Comparator Studies: Performance of Four Missing Data-Handling Approaches, Stratified by Four Different Marginal Estimators.

IF 3.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Gerd Rippin, Héctor Sanz, Wilhelmina E Hoogendoorn, Joan A Largent
{"title":"External Comparator Studies: Performance of Four Missing Data-Handling Approaches, Stratified by Four Different Marginal Estimators.","authors":"Gerd Rippin, Héctor Sanz, Wilhelmina E Hoogendoorn, Joan A Largent","doi":"10.1007/s40264-025-01586-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Missing data and unmeasured confounding may bias results of external comparator (EC) studies. Previous research quantified these effects, but there were still knowledge gaps in terms of studying a broader set of missing data-handling approaches. This knowledge gap is addressed by investigating four different ways to handle missing data for a set of four distinct marginal estimators.</p><p><strong>Methods: </strong>An extensive simulation study was conducted based on two real EC case studies. Four different variants of missing data-handling approaches were assessed in terms of bias and other performance characteristics. Specifically, multiple imputation (MI) for the trial and EC cohorts was conducted by applying within-cohort MI, across-cohort MI and a mixed within-across-cohort MI scheme. Dropping a covariate from the analysis model if missingness exceeded a certain threshold was also added as an analysis strategy. All simulation results were generated for a set of four marginal estimators: the average treatment effect of the untreated (ATU), the average treatment effect (ATE), the average treatment effect of the treated (ATT), and the average treatment effect in the overlap population (ATO). Missingness was simulated to occur only in the EC cohort, and propensity score weighting was applied as causal inference method.</p><p><strong>Results: </strong>Overall, within-cohort MI and the ATU showed best performance in terms of mitigating bias, while the strategy of leaving out prognostic factors (covariates) due to a higher percentage of missingness performed worst.</p><p><strong>Conclusions: </strong>Performances of four missing data-handling strategies were assessed for a set of four different marginal estimators. Our results add clarity with regard to potential residual bias for researchers conducting EC studies when using propensity score weighting in the case of missing data or unmeasured confounding. This enables researchers to select most appropriate statistical approaches to minimise bias, potentially by including an additional bias estimation and correction step.</p>","PeriodicalId":11382,"journal":{"name":"Drug Safety","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40264-025-01586-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Missing data and unmeasured confounding may bias results of external comparator (EC) studies. Previous research quantified these effects, but there were still knowledge gaps in terms of studying a broader set of missing data-handling approaches. This knowledge gap is addressed by investigating four different ways to handle missing data for a set of four distinct marginal estimators.

Methods: An extensive simulation study was conducted based on two real EC case studies. Four different variants of missing data-handling approaches were assessed in terms of bias and other performance characteristics. Specifically, multiple imputation (MI) for the trial and EC cohorts was conducted by applying within-cohort MI, across-cohort MI and a mixed within-across-cohort MI scheme. Dropping a covariate from the analysis model if missingness exceeded a certain threshold was also added as an analysis strategy. All simulation results were generated for a set of four marginal estimators: the average treatment effect of the untreated (ATU), the average treatment effect (ATE), the average treatment effect of the treated (ATT), and the average treatment effect in the overlap population (ATO). Missingness was simulated to occur only in the EC cohort, and propensity score weighting was applied as causal inference method.

Results: Overall, within-cohort MI and the ATU showed best performance in terms of mitigating bias, while the strategy of leaving out prognostic factors (covariates) due to a higher percentage of missingness performed worst.

Conclusions: Performances of four missing data-handling strategies were assessed for a set of four different marginal estimators. Our results add clarity with regard to potential residual bias for researchers conducting EC studies when using propensity score weighting in the case of missing data or unmeasured confounding. This enables researchers to select most appropriate statistical approaches to minimise bias, potentially by including an additional bias estimation and correction step.

外部比较研究:四种缺失数据处理方法的性能,由四种不同的边际估计器分层。
背景和目的:缺失数据和未测量的混杂因素可能使外部比较器(EC)研究的结果偏倚。之前的研究量化了这些影响,但在研究更广泛的缺失数据处理方法方面仍然存在知识空白。通过研究四种不同的方法来处理一组四个不同的边际估计器的缺失数据,解决了这种知识差距。方法:基于两个真实的EC案例进行了广泛的模拟研究。根据偏差和其他性能特征评估了缺失数据处理方法的四种不同变体。具体而言,通过应用队列内MI、跨队列MI和混合跨队列MI方案,对试验和EC队列进行了多重imputation (MI)。如果缺失超过一定的阈值,从分析模型中删除协变量也被添加为一种分析策略。所有的模拟结果都是为一组四个边际估计量生成的:未处理的平均处理效果(ATU)、平均处理效果(ATE)、处理的平均处理效果(ATT)和重叠群体中的平均处理效果(ATO)。模拟缺失只发生在EC队列中,并采用倾向得分加权作为因果推理方法。结果:总体而言,队列内MI和ATU在减轻偏倚方面表现最佳,而由于缺失率较高而忽略预后因素(协变量)的策略表现最差。结论:四种缺失数据处理策略的性能被评估为一组四种不同的边际估计器。我们的结果为研究人员在缺少数据或未测量的混杂情况下使用倾向评分加权进行EC研究时增加了关于潜在残留偏倚的清晰度。这使研究人员能够选择最合适的统计方法来最小化偏差,可能包括额外的偏差估计和校正步骤。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Safety
Drug Safety 医学-毒理学
CiteScore
7.60
自引率
7.10%
发文量
112
审稿时长
6-12 weeks
期刊介绍: Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes: Overviews of contentious or emerging issues. Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes. In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area. Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement. Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics. Editorials and commentaries on topical issues. Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Drug Safety Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信